Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Cancer medicines outcomes programme: better use of data to understand outcomes in a local population
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-HMI-022
- By: LASKEY, Jennifer (NHS Greater Glasgow and Clyde, PPSU)
- Co-author(s): Jennifer Laskey
Yvonne Semple: PPSU, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Olivia Wu: Health economics, University of Glasgow, Glasgow, United Kingdom
Julie Clarke: PPSU, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Kelly baillie: PPSU, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Tanja Mueller: Pharmacy, University of Strathclyde, Glasgow, United Kingdom
Jiafeng Pan: Pharmacy, University of Strathclyde, Glasgow, United Kingdom
Rob Jones: medicine, University of Glasgow, Glasgow, United Kingdom
Ashita Waterston: medicine, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Marion Bennie: Pharmacy, University of Strathclyde, Glasgow, United Kingdom - Abstract:
Background
Cancer medicines account for the highest proportion of new medicines introduced within NHS Scotland each year. Most information about efficacy and safety of new medicines is derived from clinical trials. There is an increasing interest in ‘real world’ data to understand local population outcomes.1,2,3
Methods
Melanoma and prostate cancer
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023